Clinical Trials

Sponsor: Viracta Therapeutics, Inc.

Sponsor Study ID: VT3996-202

Study Title: An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)

NCT Number: NCT05011058

Phase: II

Protocol Type: Treatment

Age Group: Both

Disease Sites: Other Hematopoietic

Study Objectives: A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas.

For more information about the trial above please contact the study team:

Principal Investigator, Irl Greenwell, at greenwe@musc.edu, or please call +1 843-792-4759.
Study Coordinator, Sarah Milligan, at millisar@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)